Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 18/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16013986 | 0.87 | MKNK1 (1.00) | MKNK1 | |
| SCHEMBL16013950 | 0.85 | MKNK1 (0.67) | MKNK1 | |
| SCHEMBL16013831 | 0.83 | MKNK1 (0.66) | MKNK1KDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL16013949 | 0.82 | MKNK1 (0.95) | MKNK1 | |
| SCHEMBL16013227 | 0.81 | MKNK1 (1.00) | MKNK1 | |
| SCHEMBL16013305 | 0.80 | MKNK1 (1.00) | MKNK1 | |
| SCHEMBL16013526 | 0.80 | MKNK1 (1.00) | MKNK1MEN1KMT2A | |
| SCHEMBL17026094 | 0.74 | MKNK1 (0.67) | MKNK1 | |
| SCHEMBL15618197 | 0.72 | MKNK1 (0.64) | MKNK1KDM4EMAPTPOLBL3MBTL1 | |
| SCHEMBL15618199 | 0.72 | MKNK1 (0.61) | MKNK1KDM4EMAPTPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675612-B2 | Substituted thiazolopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-13 | — | — | US | claimed |
| US-20160009734-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-14 | — | — | US | claimed |
| EP-2964656-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-13 | — | — | EP | claimed |
| WO-2014135480-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-12 | — | — | WO | claimed |
| US-9675612-B2 | Substituted thiazolopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20160009734-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009734-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | DPYD, TYMP, THPO | MKNK1 3409/4885KDM4E 2803/4885MAPT 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.